NEW: No-Cost Streetwise Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: RVV; RVVTF

Life Sciences Firm Signs MOU for Phase 3 COVID-19 Study
News Update

Share on Stocktwits

Source:

Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19.

In a news release, Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) announced that it has "signed a Memorandum of Understanding (MOU) with Attwill Medical Solutions Sterilflow L.P. (AMS) to establish AMS as a resource for clinical packaging and distribution for the company's Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19."

The company's CEO Michael Frank commented, "We are pleased to engage in formal discussions with Attwill Medical to assist us in the clinical packaging and distribution for our Phase 3 clinical study in COVID-19, as they have the resources and capabilities to execute on a number of activities that are critical to large-scale clinical studies."

The firm pointed out that "AMS is one of the largest contract Lyophilization services facilities in the U.S. and recently announced a MOU with Vaxart Inc. (VXRT:NASDAQ) affirming the parties' intent to establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart's oral COVID-19 vaccine."

The company advised that the scope of work specified in the MOU calls for the two firms to collaborate in the area of clinical packaging. Revive indicated that in the Phase 3 COVID-19 clinical study, AMS may be contracted to assist in analytical and stability studies, clinical supply chain management, storage, distribution and project management.

The company disclosed that the agreement is classified as a "related party transaction" as defined under Multilateral Instrument 61-101—Protection of Minority Security Holders in Special Transactions since Revive Director Bill Jackson is also an AMS insider. The firm noted though that as the fair market value of the consideration to be paid to AMS will not exceed 25% of Revive's market cap, the transaction with AMS is exempt from the formal valuation and minority shareholder approval requirements under MI 61-101.

Revive Therapeutics additionally announced that it has initiated the process to have its common shares upgraded and quoted on the U.S. OTCQB Market exchange. The company stated that one benefit of moving to the OTCQB in the U.S. is that it will help introduce the company to a wider range of retail and institutional investors.

Revive Therapeutics Ltd. is a life sciences company based in Toronto, Ont., Canada that focuses on developing therapeutics for rare disorders and infectious diseases. The firm stated that at this time "it is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus)."

[NLINSERT]

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Revive Therapeutics. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.




Learn More about Streetwise Reports Live

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe